Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07671092 | Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC | recruiting | Early Phase 1 | 40 | RayzeBio, Inc.INDUSTRY | 2 | Sep 29, 2026 | clinicaltrials |
| NCT06097962 | Safety and Efficacy of NK510 to Treat NSCLC | recruiting | Early Phase 1 | 12 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07793500 |
| YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC) |
| recruiting |
| Early Phase 1 |
| 36 |
| Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER |
| 1 |
| Aug 28, 2026 |
| clinicaltrials |
| NCT07689643 | Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer | recruiting | Early Phase 1 | 36 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07274813 | A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors | recruiting | Early Phase 1 | 254 | Shanghai Henlius BiotechINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07235280 | Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma | recruiting | Early Phase 1 | 48 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05493566 | Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer | recruiting | Early Phase 1 | 15 | Emory UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05620342 | Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | recruiting | Early Phase 1 | 24 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06639191 | [177Lu]Lu-AKIR001 First-in-human Study(AKIR001) | recruiting | Early Phase 1 | 15 | Karolinska University HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05060796 | Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC | recruiting | Early Phase 1 | 11 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
Data updated 18 hours agoSource updated Sep 29, 2026source: clinicaltrials